Gamma-delta T Cells may Function as Carrier Vehicles in Adenovirus Vector-based Gene Therapy
- *Corresponding Author:
- Michio Naoe, M.D
Department of Urology, Showa University
1-5-8, Hatanodai, Shinagawa-ku, Tokyo, Japan
E-mail: [email protected]
Received Date: September 10, 2013; Accepted Date: November 05, 2013; Published Date: November 08, 2013
Citation: Naoe M, Ogawa Y, Hasebe Y, Fuji K, Iwamoto S, et al. (2013) Gammadelta T Cells may Function as Carrier Vehicles in Adenovirus Vector-based Gene Therapy. J Cancer Sci Ther 5:384-390. doi: 10.4172/1948-5956.1000230
Copyright: © 2013 Naoe M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Developing new treatments that reduce prostate cancer progression is important. Therapeutic efficacy of conventional gene therapy for metastatic prostate cancer is still low. Lower induction rate of naked genes into target cell is due to reduced expression of adenovirus receptor on cancer cell and also due to high seroprevalence of anti-Ad antibodies in adults. Therefore, efficient Ad carrier systems that circumvent these problems should be developed. Gamma-delta T cells have demonstrated high affinity to cancer cells. CD46, which leads to broad tropism in Ad35 vectors, is expressed in hematopoietic cells, including γδ T cells. In this study, we demonstrate the potential of γδ T cells as “vehicles” for transporting Ad5/F35 vectors and genes into cancer cells.